Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next ...
Trinity Biotech engages Barclays to advise on strategic realignment process
Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose ...
Trinity Biotech receives non-compliance notice from Nasdaq
Trinity Biotech (TRIB) received notice from the Nasdaq Stock Market LLC that the company is not in compliance with Nasdaq Listing Rule ...
Nasdaq6d
Trinity Biotech Appoints Barclays Capital as Exclusive Financial Advisor to Advance Continuous Glucose Monitoring Technology Transformation Plan
Trinity Biotech plc announced a significant step in its transformation plan by appointing Barclays Capital Inc. as its exclusive financial advisor. The company is shifting its focus to developing ...
Drug Delivery Business6d
Trinity Biotech to undergo strategic realignment, focus on CGM development
Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.
ETF Daily News4d
Trinity Biotech (NASDAQ:TRIB) Coverage Initiated by Analysts at StockNews.com
Shares of Trinity Biotech stock opened at $0.69 on Friday. The firm has a market cap of $12.37 million, a price-to-earnings ratio of -0.30 and a beta of 1.20. The business has a 50-day moving ...
Nasdaq4d
Trinity Biotech plc Receives Nasdaq Compliance Notice Regarding Bid Price and Market Value Requirements
Trinity Biotech received Nasdaq notices for non-compliance with bid price and market value requirements, with 180 days to address deficiencies. Trinity Biotech plc, a biotechnology company ...
HME News6d
Trinity Biotech zeroes in on CGM
Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...
Mena FN6d
Trinity Biotech Further Strengthens Focus On Continuous Glucose Monitoring – Appoints Barclays To Advise On Ongoing Strategic Realignment Process
(MENAFN- GlobeNewsWire - Nasdaq) DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human ...